Dyne Therapeutics, Inc.
DYN
$20.09
$0.100.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.66% | 70.69% | -35.31% | 73.03% | 83.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.79% | 60.91% | 76.95% | 43.46% | 69.67% |
| Operating Income | -7.79% | -60.91% | -76.95% | -43.46% | -69.67% |
| Income Before Tax | -11.24% | -70.28% | -75.72% | -34.37% | -61.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.24% | -70.28% | -75.72% | -34.37% | -61.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.24% | -70.28% | -75.72% | -34.37% | -61.31% |
| EBIT | -7.79% | -60.91% | -76.95% | -43.46% | -69.67% |
| EBITDA | -7.74% | -61.10% | -77.21% | -43.65% | -70.14% |
| EPS Basic | 20.87% | -38.34% | -29.58% | 19.11% | 2.28% |
| Normalized Basic EPS | 20.86% | -38.34% | -29.57% | 19.10% | 2.29% |
| EPS Diluted | 20.87% | -38.34% | -29.58% | 19.11% | 2.28% |
| Normalized Diluted EPS | 20.86% | -38.34% | -29.57% | 19.10% | 2.29% |
| Average Basic Shares Outstanding | 40.57% | 23.10% | 35.62% | 66.11% | 65.08% |
| Average Diluted Shares Outstanding | 40.57% | 23.10% | 35.62% | 66.11% | 65.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |